Subacute sclerosing panencephalitis overview

Jump to navigation Jump to search

Subacute sclerosing panencephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Subacute sclerosing panencephalitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Subacute sclerosing panencephalitis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Subacute sclerosing panencephalitis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Subacute sclerosing panencephalitis overview

CDC on Subacute sclerosing panencephalitis overview

Subacute sclerosing panencephalitis overview in the news

Blogs on Subacute sclerosing panencephalitis overview

Directions to Hospitals Treating Subacute sclerosing panencephalitis

Risk calculators and risk factors for Subacute sclerosing panencephalitis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Subacute sclerosing panencephalitis is a rare chronic, progressive encephalitis that affects primarily children and young adults, caused by defective measles virus (which can be a result of a mutation of the virus itself). SSPE is 'incurable' but the condition can be managed by medication if treatment is started at an early stage. Much of the work on SSPE has been completed by the NINDS.

Causes

Ordinarily, the measles virus does not cause brain damage, but an abnormal immune response to measles or, possibly, certain mutant forms of the virus may cause severe illness and death. This leads to brain inflammation (swelling and irritation) that may last for years.

Epidemiology and Demographics

SSPE is an incredibly rare condition although there is still relatively high incidence in Asia and the Middle East. However, the number of reported cases is declining since the introduction of the measles vaccine — eradication of the measles virus prevents the SSPE mutation and therefore the progression of the disease or even the initial infection itself.

Risk Factors

SSPE tends to occur several years after an individual has measles, even though the person seems to have fully recovered from the illness. 1 in 100,000 people infected with measles are at risk.

Diagnosis

History and Symptoms

Characterized by a history of primary measles infection before the age of 2 years, followed by several asymptomatic years (6–15 on average), and then gradual, progressive psychoneurological deterioration, consisting of personality change, seizures, myoclonus, ataxia, photosensitivity, ocular abnormalities, spasticity, and coma.

Treatment

Medical Therapy

No cure for SSPE exists. However, certain antiviral drugs may slow the progression of the disease.

Primary Prevention

Immunization against measles is the only known prevention for SSPE. The measles vaccine has been highly effective in reducing the numbers of affected children.

Measles immunization should be done according to the recommended American Academy of Pediatrics and Centers for Disease Control schedule.

References

Template:WH Template:WS